An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting Athanassios P. KyritsisVictor A. Levin Mini Review 27 March 2011 Pages: 971 - 983
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients Chee M. NgA. PatnaikC. H. Takimoto Original Article 08 July 2010 Pages: 985 - 994
Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent Carol E. GreenRobert SwezeyIzet M. Kapetanovic Original Article 10 July 2010 Pages: 995 - 1006
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype Kenjiro AogiMasayuki YoshidaShigemitsu Takashima Original Article 14 July 2010 Pages: 1007 - 1015
H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein Ning WeiHua SunGengtao Liu Original Article 17 July 2010 Pages: 1017 - 1025
Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma Mario AiroldiPietro GabrieleCarlo Giordano Original Article 20 July 2010 Pages: 1027 - 1034
Sunitinib improves chemotherapeutic efficacy and ameliorates cisplatin-induced nephrotoxicity in experimental animals Ghada M. Suddek Original Article 22 July 2010 Pages: 1035 - 1044
Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations Howard A. Burris IIIDavid BermanSuzanne Jones Original Article 23 July 2010 Pages: 1045 - 1054
Increasing tumoral 5-fluorouracil concentrations during a 5-day continuous infusion: a microdialysis study Inge R. H. M. KoningsStefan SleijferWalter J. Loos Original Article Open access 23 July 2010 Pages: 1055 - 1062
Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects Riyo EnomotoChika KoshibaEibai Lee Original Article 24 July 2010 Pages: 1063 - 1072
Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase Sunny GuinQi MaMing-Hai Wang Original Article 25 July 2010 Pages: 1073 - 1083
Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis C. A. C. X. MedeirosR. F. C. LeitãoG. A. C. Brito Original Article 27 July 2010 Pages: 1085 - 1100
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors Yutaka UedaTatsu ShimoyamaTomohide Tamura Original Article Open access 30 July 2010 Pages: 1101 - 1109
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study T. WaddellS. GollinsM. P. Saunders Original Article 30 July 2010 Pages: 1111 - 1117
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors Haruyasu MurakamiYutaka UedaTomohide Tamura Original Article Open access 31 July 2010 Pages: 1119 - 1128
Rapamycin suppresses ROS-dependent apoptosis caused by selenomethionine in A549 lung carcinoma cells Maiko SuzukiManabu EndoHidemi Rikiishi Original Article 03 August 2010 Pages: 1129 - 1136
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates M. JoergerA. TempletonB. Thürlimann Original Article 04 August 2010 Pages: 1137 - 1144
A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity Kashyap PatelSteve S. F. ChoyWilliam R. Wilson Original Article 04 August 2010 Pages: 1145 - 1155
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs Anja FrömbergDaniela GutschAchim Aigner Original Article Open access 08 August 2010 Pages: 1157 - 1166
Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death Bettina M. KaminskiAndreas WeigertSandra Ulrich Original Article 06 August 2010 Pages: 1167 - 1178
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity Michele BassoAnna ModoniCarlo Barone Original Article 25 September 2010 Pages: 1179 - 1187
The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects? Susanna B. ParkCindy S-Y. LinMatthew C. Kiernan Letter to the Editor 16 February 2011 Pages: 1189 - 1190
Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells Jorge Humberto Tapia-PérezElmar KirchesThomas Schneider Short Communication 01 December 2010 Pages: 1193 - 1201
A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer Christos ChouaidFaith NathanThomas Morris Short Communication 14 December 2010 Pages: 1203 - 1208
Erratum to: Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice Yongchuan GuChristopher P. GuiseWilliam R. Wilson Erratum 19 March 2011 Pages: 1209 - 1209
